Stay updated on Pembrolizumab + Imprime PGG in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page
- CheckyesterdayChange DetectedRevision: v3.5.4 was added and v3.5.3 was deleted, indicating a page version update.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page’s UI/version marker was bumped from “v3.5.2” to “v3.5.3,” indicating a site revision update rather than a change to the clinical study information.SummaryDifference0.0%

- Check29 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check58 days agoChange DetectedRevision tag updated to v3.5.0. The previous revision v3.4.3 was removed.SummaryDifference0.0%

- Check65 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed from the page's revision history.SummaryDifference0.0%

- Check94 days agoChange DetectedThe page now displays Revision: v3.4.2 (replacing Revision: v3.4.1). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab + Imprime PGG in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Imprime PGG in NSCLC Clinical Trial page.